NASDAQ: FDMT4d Molecular Therapeutics Inc Stock
$23.53-0.72 (-2.97%)
Updated Apr 25, 2024
FDMT Price
$23.53
Fair Value Price
-$9.95
Market Cap
$1.17B
52 Week Low
$9.44
52 Week High
$36.25
P/E
-9.12x
P/B
3.8x
P/S
38.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.72M
Earnings
-$100.84M
Gross Margin
100%
Operating Margin
-486.59%
Profit Margin
-486.6%
Debt to Equity
0.1
Operating Cash Flow
-$76M
Beta
1.31
Next Earnings
May 21, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FDMT Overview
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy that uses adeno-associated virus vectors to develop product candidates in three therapeutic areas: ophthalmology, cardiology, and pulmonology. 4D Molecular Therapeutics has research and collaboration arrangements with uniQure, CRF, Roche, and CFF. The company was founded in 2013 and is headquartered in Emeryville, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FDMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FDMT ($23.53) is overvalued by 336.41% relative to our estimate of its Fair Value price of -$9.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FDMT ($23.53) is not significantly undervalued (336.41%) relative to our estimate of its Fair Value price of -$9.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FDMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FDMT due diligence checks available for Premium users.
Be the first to know about important FDMT news, forecast changes, insider trades & much more!
FDMT News
Valuation
FDMT fair value
Fair Value of FDMT stock based on Discounted Cash Flow (DCF)
Price
$23.53
Fair Value
-$9.95
Undervalued by
336.41%
FDMT ($23.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FDMT ($23.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FDMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FDMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.12x
Industry
15.41x
Market
40.97x
FDMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.8x
Industry
5.8x
FDMT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FDMT's financial health
Profit margin
Revenue
-$19.0k
Net Income
-$32.3M
Profit Margin
169,910.5%
FDMT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FDMT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$339.9M
Liabilities
$32.1M
Debt to equity
0.1
FDMT's short-term assets ($296.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FDMT's short-term assets ($296.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FDMT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FDMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.7M
Investing
-$6.7M
Financing
$4.8M
FDMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FDMT vs Biotech Stocks
4d Molecular Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.